The manufacturer of a breast cancer drug that offers a last hope to patients could have been "more flexible" to help make the drug affordable for the NHS, a health service boss said.
Sir Andrew Dillon, chief executive of the NHS financial watchdog Nice, which has ruled Kadcyla is too expensive for NHS use, said:
Although Roche proposed a discount to the full list price of Kadcyla, it made little difference to its value for money, leaving it well above the top of our specially extended range of cost effectiveness for cancer drugs.
We are really disappointed that Roche were not able to demonstrate more flexibility to help us make a positive recommendation. The company is well aware that we could not have recommend Kadcyla at the price it proposed.
More top news
An Ofcom report says mistakes mean people relying on live subtitles had an 'inferior' experience to other viewers.
Waitrose is to scrap a hot drink free-for-all which allowed loyalty card holders to enjoy free drinks in its cafes without buying anything.
A new wave of antisemitism in Belgium sits uncomfortably alongside the ceremonies to remember the liberation of Auschwitz 70 years ago.